Node1	Edge_Type	Node2	Weight	Score	Paper_List	Original_Text
naltrexone	chemical_to_anatomy	of the	2	0	9028057|7654128	"PMID:9028057; Original text:The behavioural evaluation was conducted using the specific BSE and CARS rating scales naltrexone treatment produced a significant reduction of the autistic symptomatology in seven (""responders"") out of 12 children.|PMID:7654128; Original text:On the contrary, naltrexone increased the incidence of stereotypic behavior on the Aberrant Behavior Checklist, and the care staff evaluated the effect of the 50-mg/d treatment as being significantly worse than that of the placebo treatment as measured by the Clinical Global Impression Scale."
oxytocin	chemical_to_anatomy	, 2	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	chemical_to_anatomy	2	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	chemical_to_anatomy	facial expression	3	0	31096266|31096266|33622389	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:31096266; Original text:Quantitative facial expression analyses successfully verified the positive effects of repeated oxytocin on autistic individuals' facial expressions and demonstrated a time-course change in efficacy.|PMID:33622389; Original text:The increase in N,N-dimethylglycine was significantly correlated with oxytocin-induced clinical changes, assessed as changes in quantifiable characteristics of autistic facial expression, including both of improvements between baseline and 2 weeks (Pfalse discovery rate = 0.006, r = - 0.485, N = 43) and deteriorations between 2 and 4 weeks
oxytocin	chemical_to_anatomy	4	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
oxytocin	chemical_to_anatomy	, and	4	0	31096266|24352377|25092245|28467893	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).|PMID:25092245; Original text:Thus, a meta-analytic review of extant studies is needed to determine whether The oxytocin receptor gene shows association with disorder, and to elucidate which specific single-nucleotide polymorphisms have a significant effect on disorder.|PMID:28467893; Original text:A single dose of intranasal oxytocin significantly improved the recognition of basic emotions, particularly fear, and increased the expression of positive emotions among the healthy individuals.
oxytocin	chemical_to_anatomy	(p	8	0	31096266|34062986|24352377|24352377|24352377|26336909|31229634|25149412	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).|PMID:34062986; Original text:We observed improvements in Aberrant Behavior Checklist and the Social Responsiveness Scale scores and significant improvements in the Clinical Global Impression-improvement between those receiving probiotics and oxytocin combination therapy compared to those receiving placebo (p < 0.05).|PMID:24352377; Original text:Intranasal oxytocin enabled the participants to make the nonverbal information-based judgments more frequently (P = .03) with shorter response time (P = .02).|PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).|PMID:26336909; Original text:Data obtained from 18 participants who completed the trial showed that 6-week intranasal administration of oxytocin significantly reduced autism core symptoms specific to social reciprocity, which was clinically evaluated by Autism Diagnostic Observation Scale (P = 0.034, PFDR < 0.05, Cohen's d = 0.78).|PMID:31229634; Original text:Results revealed a marginal significant interaction effect between treatment, condition and task (p = 0.054), with Bonferroni-corrected post-hoc tests indicating that The neuropeptide oxytocin specifically increased antisaccade errors for social stimuli (ps < 0.04, effect sizes 0.46-0.88), but not non-social stimuli.|PMID:25149412; Original text:Behaviourally, oxytocin significantly increased the correct rate in inferring others' social emotions (P = 0.043, one-tail).
oxytocin	chemical_to_anatomy	6	1	0	31096266	PMID:31096266; Original text:A significant interaction between time-course (at baseline, 2, 4, 6, and 8 weeks) and the efficacy of oxytocin on the natural logarithm of mode on the probability density function of neutral facial expression was found in confirmatory trial (P < 0.001).
n-acetylcysteine	chemical_to_anatomy	, oral	1	0	22342106	PMID:22342106; Original text:Compared with placebo, oral N-acetylcysteine resulted in significant improvements on ABC irritability subscale (F = 6.80; p < .001; d = .96).
cortisol	chemical_to_anatomy	salivary	1	0	31657508	PMID:31657508; Original text:After the training sessions, the participants' self-confidence had improved and salivary cortisol levels were significantly decreased in the Simple Virtual Audiences group as compared to those in the independent study group.
carnosine	chemical_to_anatomy	(p	1	0	29430839	PMID:29430839; Original text:Carnosine supplementation did not change anthropometric indices (p > 0.05) and showed no effect on autism severity (p > 0.05), whereas it significantly reduced sleep duration (p = 0.04), parasomnias (p = 0.02) and total sleep disorders score by 7.59% (p = 0.006) when compared with the control group.
resveratrol	chemical_to_anatomy	, and	1	0	31714621	PMID:31714621; Original text:In contrast, patients in the resveratrol group showed greater decline in hyperactivity/non-compliance score as a secondary outcome measure (mean difference [CI = 95%] = 4.51 [0.10-8.92], t = 2.04; P = .04), and repeated measures analysis showed significant effect for time × treatment effect on this subscale score (F = 3.81; df = 1.30; P = .043).
resveratrol	chemical_to_anatomy	, t	1	0	31714621	PMID:31714621; Original text:In contrast, patients in the resveratrol group showed greater decline in hyperactivity/non-compliance score as a secondary outcome measure (mean difference [CI = 95%] = 4.51 [0.10-8.92], t = 2.04; P = .04), and repeated measures analysis showed significant effect for time × treatment effect on this subscale score (F = 3.81; df = 1.30; P = .043).
risperidone	chemical_to_anatomy	group (	7	0	9672054|12151468|12151468|12151468|18080171|18080171|16948927	PMID:9672054; Original text:For persons completing the study, 8 (57%) of 14 patients treated with risperidone were categorized as responders (daily dose [mean+/-SD], 2.9+/-1.4 mg) compared with none of 16 in the placebo group (P<.002).|PMID:12151468; Original text:Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001).|PMID:12151468; Original text:The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the the Clinical Global Impressions - Improvement scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of placebo, P<0.001).|PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).|PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
risperidone	chemical_to_anatomy	, and	9	0	9672054|12151468|22784311|22784311|18439113|15930063|24828014|15492353|15492353	PMID:9672054; Original text:Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02).|PMID:12151468; Original text:Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison).|PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.|PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.|PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).|PMID:24828014; Original text:Six of the 48 subjects met two criteria for responders to risperidone, and the median values of interleukin (interleukin)-5 were significantly higher (p=0.005) in the overall responder group than in nonresponders.|PMID:15492353; Original text:Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the the Aberrant Behavior Checklist; on the conduct problem, insecure/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom.|PMID:15492353; Original text:Risperidone-treated subjects experienced statistically significantly greater increases in weight (2.7 vs 1.0 kg), pulse rate, and systolic blood pressure.
sumatriptan	chemical_to_anatomy	growth hormone	2	0	10808042|10649829	PMID:10808042; Original text:This suggests that autistic patients had significantly greater growth hormone response to sumatriptan than normal controls, independent of placebo effects.|PMID:10649829; Original text:In adult autistic disorders, severity of repetitive behaviors at baseline, as measured by YBOCS-compulsion score, significantly positively correlated with both peak delta growth hormone response and area under the curve growth hormone response to sumatriptan.
oxytocin	chemical_to_anatomy	, a	2	0	33622389|25092245	PMID:33622389; Original text:Among the 35 metabolites measured, a significant increase in N,N-dimethylglycine was detected in the subjects administered oxytocin compared with those given placebo at a medium effect size (false discovery rate (false discovery rate) corrected P = 0.043, d = 0.74, N = 83).|PMID:25092245; Original text:Thus, a meta-analytic review of extant studies is needed to determine whether The oxytocin receptor gene shows association with disorder, and to elucidate which specific single-nucleotide polymorphisms have a significant effect on disorder.
oxytocin	chemical_to_anatomy	of the	6	0	33622389|27071789|24352377|32161366|27651096|8759044	"PMID:33622389; Original text:Furthermore, subgroup analyses of the participants displaying a prominent time-course change in oxytocin efficacy revealed a significant effect of oxytocin on N,N-dimethylglycine levels with a large effect size (Pfalse discovery rate = 0.004, d = 1.13, N = 60).|PMID:27071789; Original text:Some studies have reported significant improvement of the core symptoms of disorder by long-term oxytocin administration, while other studies showed no such improvement.|PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:27651096; Original text:Despite these limitations in the field to date, there remains significant potential for oxytocin to ameliorate aspects of the persistent and debilitating social impairments in individuals with disorder.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_anatomy	and 2	1	0	33622389	PMID:33622389; Original text:The increase in N,N-dimethylglycine was significantly correlated with oxytocin-induced clinical changes, assessed as changes in quantifiable characteristics of autistic facial expression, including both of improvements between baseline and 2 weeks (Pfalse discovery rate = 0.006, r = - 0.485, N = 43) and deteriorations between 2 and 4 weeks
vitamin b6	chemical_to_anatomy	, and	2	0	30287864|3886023	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.|PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
glutamine	chemical_to_anatomy	, and	1	0	30287864	PMID:30287864; Original text:Statistically significant variables for vitamin B6 responsiveness, including combination of hypersensitivity to sound and clumsiness, and plasma glutamine level, were included.
neurotensin	chemical_to_anatomy	mitochondrial	1	0	23570274	PMID:23570274; Original text:neurotensin is significantly increased in serum of ASD children along with mitochondrial DNA (mitochondrial DNA).
luteolin	chemical_to_anatomy	, mast	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
luteolin	chemical_to_anatomy	mast cells	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
luteolin	chemical_to_anatomy	microglia	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
rapamycin	chemical_to_anatomy	, mast	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
rapamycin	chemical_to_anatomy	mast cells	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
rapamycin	chemical_to_anatomy	microglia	1	0	23570274	PMID:23570274; Original text:The natural flavonoid luteolin inhibits rapamycin, mast cells and microglia and could have a significant benefit in ASD.
risperidone	chemical_to_anatomy	scale	2	0	12151468|15930063	PMID:12151468; Original text:The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the the Clinical Global Impressions - Improvement scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of placebo, P<0.001).|PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).
risperidone	chemical_to_anatomy	sensory motor	4	0	18026891|15930063|18080171|18080171	PMID:18026891; Original text:There was significant improvement on RF-RLRS sensory motor and language subscale and ABC scores in risperidone group.|PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).|PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
melatonin	chemical_to_anatomy	pineal gland	1	0	21517957	PMID:21517957; Original text:Already, recent advances in understanding signalling dynamics in the human pineal gland have significantly helped to counteract chronobiological dysfunctions through a proper restoration of the nocturnal melatonin surge.
melatonin	chemical_to_anatomy	of the	2	0	21517957|12804129	PMID:21517957; Original text:Already, recent advances in understanding signalling dynamics in the human pineal gland have significantly helped to counteract chronobiological dysfunctions through a proper restoration of the nocturnal melatonin surge.|PMID:12804129; Original text:Despite the short duration of the treatment, behavioral measures also displayed a significant improvement, and most of the effect disappeared after the discontinuation of the melatonin (p = 0.001).
avp	chemical_to_anatomy	scale	1	0	31043522	PMID:31043522; Original text:Intranasal AVP treatment compared to placebo enhanced social abilities as assessed by change from baseline in this phase 2 trial's primary outcome measure, the Social Responsiveness Scale, 2nd Edition total score (SRS-2 T score; F 1,20 = 9.853; P = 0.0052; ηp  = 33.0%; Cohen's d = 1.40).
methylphenidate	chemical_to_anatomy	of joint	1	0	18752063	PMID:18752063; Original text:A significant positive effect of methylphenidate was seen on children's use of joint attention initiations, response to bids for joint attention, self-regulation, and regulated affective state.
methylphenidate	chemical_to_anatomy	, and	2	0	18752063|18439113	PMID:18752063; Original text:A significant positive effect of methylphenidate was seen on children's use of joint attention initiations, response to bids for joint attention, self-regulation, and regulated affective state.|PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
b6-mg	chemical_to_anatomy	, middle	1	0	7124567	PMID:7124567; Original text:During B6-Mg treatment, middle latency evoked potentials exhibited a significant increase of amplitude.
imipramine	chemical_to_anatomy	, and	1	0	11085201	PMID:11085201; Original text:Fluvoxamine < or = 300 mg/day for 6 to 8 weeks was as effective as imipramine in patients with panic disorder, and significantly more effective than placebo.
fluvoxamine	chemical_to_anatomy	, and	2	0	11085201|8911223	PMID:11085201; Original text:Fluvoxamine < or = 300 mg/day for 6 to 8 weeks was as effective as imipramine in patients with panic disorder, and significantly more effective than placebo.|PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
vitamin d3	chemical_to_anatomy	contact	1	0	25876214	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.
vitamin d3	chemical_to_anatomy	, eye	1	0	25876214	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.
vitamin d3	chemical_to_anatomy	of the	2	0	25876214|27868194	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.|PMID:27868194; Original text:The autism symptoms of the children improved significantly, following 4-month vitamin D3 supplementation, but not in the placebo group.
vitamin d3	chemical_to_anatomy	, and	1	0	25876214	PMID:25876214; Original text:Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span.
serotonin	chemical_to_anatomy	(p	2	0	15292671|26746121	PMID:15292671; Original text:Significantly lower platelet-poor plasma serotonin levels were observed in the autistic group as compared to the controls (p = 0.03).|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
serotonin	chemical_to_anatomy	platelet	2	0	15292671|15292671	PMID:15292671; Original text:Significantly lower platelet-poor plasma serotonin levels were observed in the autistic group as compared to the controls (p = 0.03).|PMID:15292671; Original text:In addition, platelet-poor plasma serotonin levels were inversely correlated with the Overt Aggression Scale scores among subjects with autism (r = -0.64, p < 0.05).
glutathione	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
glutathione	chemical_to_anatomy	, and	2	0	33414386|19852789	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.|PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
s-adenosylmethionine	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylmethionine	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b12	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin d	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
cysteine	chemical_to_anatomy	, and	2	0	33414386|22129897	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.|PMID:22129897; Original text:Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
calcium	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
calcium	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
methionine	chemical_to_anatomy	, and	2	0	33414386|32173856	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.|PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
vitamin e	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin e	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b9	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
vitamin b9	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical_to_anatomy	, blood	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
s-adenosylhomocysteine	chemical_to_anatomy	, and	1	0	33414386	PMID:33414386; Original text:In contrast, blood reduced glutathione (blood reduced glutathione), total glutathione (tblood reduced glutathione), blood reduced glutathione/oxidative glutathione, tblood reduced glutathione/oxidative glutathione, methionine, cysteine, vitamin B9, vitamin D, vitamin B12, vitamin E, S-adenosylmethionine/S-adenosylhomocysteine, and calcium concentrations were significantly reduced in children with disorder relative to HC children.
serotonin	chemical_to_anatomy	striatum	1	0	28738293	PMID:28738293; Original text:However, the increased serotonin transporter (SERT) level in the striatum after treatment was correlated significantly with increased negative emotional response to human faces.
oxytocin	chemical_to_anatomy	prefrontal cortex	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	chemical_to_anatomy	medial prefrontal	4	0	24352377|26336909|26336909|30262887	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).|PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
oxytocin	chemical_to_anatomy	medial prefrontal cortex	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	chemical_to_anatomy	cortex (	2	0	24352377|26336909	PMID:24352377; Original text:During the mitigated behavior, oxytocin increased the originally diminished brain activity in the medial prefrontal cortex (P < .001).|PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	chemical_to_anatomy	area (	1	0	24352377	PMID:24352377; Original text:Moreover, oxytocin enhanced functional coordination in the area (P < .001), and the magnitude of these neural effects was predictive of the behavioral effects (P ≤ .01).
lamotrigine	chemical_to_anatomy	scales	1	0	11450816	PMID:11450816; Original text:We did not find any significant differences in improvements between lamotrigine or placebo groups on the Autism Behavior Checklist, the Aberrant Behavior Checklist, the Vineland Adaptive Behavior scales, the PL-ADOS, or the CARS.
iloperidone	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
iloperidone	chemical_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
paliperidone	chemical_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
asenapine	chemical_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
aripiprazole	chemical_to_anatomy	of the	2	0	22784311|31063671	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
aripiprazole	chemical_to_anatomy	, and	4	0	22784311|22784311|20973712|19797985	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.|PMID:20973712; Original text:Statistically significantly greater improvement was seen with aripiprazole versus placebo (p < 0.05) for all arms in both trials on the the Aberrant Behavior Checklist-Irritability total subscale score and on the following individual the Aberrant Behavior Checklist-Irritability items: Mood changes quickly, cries/screams inappropriately, and stamps feet/bangs objects.|PMID:19797985; Original text:At week 8, mean weight change (last observation carried forward) was as follows: placebo +0.3 kg, aripiprazole 5 mg/day +1.3 kg, 10 mg/day +1.3 kg, and 15 mg/day +1.5 kg; all p < .05 versus placebo.
a	chemical_to_anatomy	of the	2	0	22784311|31063671	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
a	chemical_to_anatomy	, and	2	0	22784311|22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
quetiapine	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine	chemical_to_anatomy	, and	2	0	22784311|22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:22784311; Original text:The significant findings in the updated review include (a) small but statistically significant benefits for olanzapine, aripiprazole, and risperidone for elderly patients with dementia; (b) quetiapine appears superior to placebo for general anxiety disorder (general anxiety disorder); (c) risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; and (d) adverse events are common.
quetiapine xr	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
quetiapine xr	chemical_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
olanzapine	chemical_to_anatomy	, and	2	0	22784311|26792761	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)
fluoxetine	chemical_to_anatomy	of the	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
fluoxetine	chemical_to_anatomy	, and	1	0	22784311	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.
risperidone	chemical_to_anatomy	of the	7	0	22784311|18080171|24828014|24828014|31063671|15492353|15492353	PMID:22784311; Original text:Since the 2006 review, significant developments occurred in the use of atypical antipsychotics, including FDA approval of the atypical antipsychotics asenapine, iloperidone, and paliperidone and FDA approval of previous off-label uses: (a) quetiapine and quetiapine XR as monotherapy in bipolar depression; (b) quetiapine XR as augmentation therapy for MDD; (c) aripiprazole as augmentation therapy for MDD; (d) olanzapine/fluoxetine combination for MDD; (e) olanzapine/fluoxetine combination for bipolar depression; and (f) risperidone and aripiprazole for autism spectrum disorders.|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).|PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).|PMID:24828014; Original text:Six of the 48 subjects met two criteria for responders to risperidone, and the median values of interleukin (interleukin)-5 were significantly higher (p=0.005) in the overall responder group than in nonresponders.|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.|PMID:15492353; Original text:Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the the Aberrant Behavior Checklist (primary endpoint) compared with those who were taking placebo.|PMID:15492353; Original text:Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the the Aberrant Behavior Checklist; on the conduct problem, insecure/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom.
sah	chemical_to_anatomy	levels of	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sah	chemical_to_anatomy	, and	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
methionine	chemical_to_anatomy	levels of	2	0	32173856|24676906	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).|PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
sam	chemical_to_anatomy	levels of	1	0	32173856	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).
sam	chemical_to_anatomy	, and	2	0	32173856|22151477	PMID:32173856; Original text:Our overall analyses revealed that individuals with disorder had significantly decreased levels of methionine (22 studies; Hedges' g = -0.62; 95% confidence interval [CI]: -0.89, -0.35), SAM (8 studies; Hedges' g = -0.60; 95% CI: -0.86, -0.34), and the SAM/SAH ratio (8 studies; Hedges' g = -0.98; 95% CI: -1.30, -0.66) and significantly increased levels of SAH (8 studies; Hedges' g = 0.69; 95% CI: 0.43, 0.94).|PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
serotoninp	chemical_to_anatomy	levels of	1	0	15733932	PMID:15733932; Original text:serotoninP administration significantly increased the levels of serotonin in autistic youngsters but not in normal controls.
serotonin	chemical_to_anatomy	levels of	3	0	15733932|32305492|26746121	PMID:15733932; Original text:serotoninP administration significantly increased the levels of serotonin in autistic youngsters but not in normal controls.|PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
tryptophan	chemical_to_anatomy	of the	2	0	8911222|28799778	PMID:8911222; Original text:Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from the amino acid drink after sham depletion (P = .001).|PMID:28799778; Original text:The literature strongly suggests that Tryptophan has a significant role in the correct functionality of the brain-gut axis and immunology.
tryptophan	chemical_to_anatomy	(p	3	0	8911222|8911222|26746121	PMID:8911222; Original text:Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from the amino acid drink after sham depletion (P = .001).|PMID:8911222; Original text:Tryptophan depletion led to a significant increase in behaviors such as whirling, flapping, pacing, banging and hitting self, rocking, and toe walking (P < .05).|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
amino acid	chemical_to_anatomy	of the	1	0	8911222	PMID:8911222; Original text:Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from the amino acid drink after sham depletion (P = .001).
amino acid	chemical_to_anatomy	(p	1	0	8911222	PMID:8911222; Original text:Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from the amino acid drink after sham depletion (P = .001).
tryptophan	chemical_to_anatomy	, and	1	0	8911222	PMID:8911222; Original text:Tryptophan depletion led to a significant increase in behaviors such as whirling, flapping, pacing, banging and hitting self, rocking, and toe walking (P < .05).
atomoxetine	chemical_to_anatomy	, mixed	1	0	22721596	PMID:22721596; Original text:Baseline mean disorder-RS scores for atomoxetine versus placebo were 40.7 and 38.6; after 8 weeks, mixed-effect model repeated-measure means were 31.6 (95% confidence interval 29.2-33.9) and 38.3 (36.0-40.6), respectively, with a difference in least square means of -6.7
epa	chemical_to_anatomy	group	1	0	28379964	PMID:28379964; Original text:In the ω-3 supplementation group, higher baseline body weight predicted less plasma accumulation of both EPA [B = -0.047, (95% CI = -0.077; -0.017), β = -0.54, p = 0.003] and DHA [B = -0.02, (95% CI = -0.034; -0.007), β = -0.52, p = 0.004].
dha	chemical_to_anatomy	group	1	0	28379964	PMID:28379964; Original text:In the ω-3 supplementation group, higher baseline body weight predicted less plasma accumulation of both EPA [B = -0.047, (95% CI = -0.077; -0.017), β = -0.54, p = 0.003] and DHA [B = -0.02, (95% CI = -0.034; -0.007), β = -0.52, p = 0.004].
testosterone	chemical_to_anatomy	area (	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	inferior frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	of the	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	supplementary motor	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	anterior cingulate cortex	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	anterior cingulate	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	frontal gyrus	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	cortex)	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	supplementary motor area	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	cingulate cortex	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	cortex (	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
testosterone	chemical_to_anatomy	inferior frontal	1	0	26994483	PMID:26994483; Original text:Using functional magnetic resonance imaging (functional magnetic resonance imaging), we found that a single administration of testosterone in 16 young women significantly altered connectivity of the left the left inferior frontal gyrus with the anterior cingulate cortex (the anterior cingulate cortex) and the supplementary motor area (the supplementary motor area) during Eyes' Test performance, independent of 2D:4D ratio.
mercury	chemical_to_anatomy	of the	1	0	19106436	PMID:19106436; Original text:In conclusion, the overwhelming preponderance of the evidence favours acceptance that mercury exposure is capable of causing some disorders.
cadmium	chemical_to_anatomy	, and	1	0	28716727	PMID:28716727; Original text:These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with disorder and controls.
arsenic	chemical_to_anatomy	, and	1	0	28716727	PMID:28716727; Original text:These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with disorder and controls.
mercury	chemical_to_anatomy	, and	2	0	28716727|28965590	PMID:28716727; Original text:These findings were confirmed by meta-regression analyses indicating that development status of countries significantly influences the overall effect size of mean difference for hair arsenic, cadmium, lead, and mercury between patients with disorder and controls.|PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
reboxetine	chemical_to_anatomy	test	1	0	23503544	PMID:23503544; Original text:Significant, but modest, decreases in the severity of depressive symptoms (CDRS before vs after scores: 65.5 ± 10.8 vs 58.3 ± 8.2; paired t test, 3.1; df, 10; P =0.01) and attention-deficit/hyperactivity disorder symptoms (Attention Deficit/Hyperactivity Disorder Rating Scale before vs after: 36.4 ± 5 vs 32.8 ± 5; paired-t test, 2.94; df, 10; P = 0.015) were obtained after reboxetine treatment.
methyl b12	chemical_to_anatomy	group (	1	0	26889605	PMID:26889605; Original text:The primary outcome measure - the clinician rated the Clinical Global Impressions-Improvement score - was statistically significantly better (lower) in the methyl B12 group (2.4) than in the placebo group (3.1) (0.7 greater improvement in the methyl B12 group, 95% CI 1.2-0.2, p = 0.005).
methyl b12	chemical_to_anatomy	group	1	0	26889605	PMID:26889605; Original text:The primary outcome measure - the clinician rated the Clinical Global Impressions-Improvement score - was statistically significantly better (lower) in the methyl B12 group (2.4) than in the placebo group (3.1) (0.7 greater improvement in the methyl B12 group, 95% CI 1.2-0.2, p = 0.005).
naltrexone	chemical_to_anatomy	, and	4	0	7654128|18439113|8282676|25336035	PMID:7654128; Original text:On the contrary, naltrexone increased the incidence of stereotypic behavior on the Aberrant Behavior Checklist, and the care staff evaluated the effect of the 50-mg/d treatment as being significantly worse than that of the placebo treatment as measured by the Clinical Global Impression Scale.|PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.|PMID:8282676; Original text:In the present study, naltrexone significantly reduced only hyperactivity, and no serious untoward effects were observed.|PMID:25336035; Original text:low-dose naltrexone improved pain tolerance as shown by a significant increase on Cold pressor times for post detoxification patients from 16 seconds to 55 seconds and in fibromyalgia patients from 21 seconds to 42 seconds, and improved relatedness.
folinic acid	chemical_to_anatomy	of the	1	0	27752075	PMID:27752075; Original text:Improvements in subscales of the Vineland Adaptive Behavior Scale, the Aberrant Behavior Checklist, the Autism Symptom Questionnaire and the Behavioral Assessment System for Children were significantly greater in the folinic acid group as compared with the placebo group.
folinic acid	chemical_to_anatomy	scale	1	0	27752075	PMID:27752075; Original text:Improvements in subscales of the Vineland Adaptive Behavior Scale, the Aberrant Behavior Checklist, the Autism Symptom Questionnaire and the Behavioral Assessment System for Children were significantly greater in the folinic acid group as compared with the placebo group.
tianeptine	chemical_to_anatomy	, and	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
clonidine	chemical_to_anatomy	, and	1	0	18439113	PMID:18439113; Original text:Five medications produced significant improvement as compared to placebo, including tianeptine, methylphenidate, risperidone, clonidine, and naltrexone.
sulforaphane	chemical_to_anatomy	scale	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
sulforaphane	chemical_to_anatomy	, a	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
sulforaphane	chemical_to_anatomy	, and	2	0	25313065|32347624	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
sulforaphane	chemical_to_anatomy	(p	3	0	25313065|25313065|32347624	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).|PMID:25313065; Original text:After 18 wk, participants receiving placebo experienced minimal change (<3.3%), whereas those receiving sulforaphane showed substantial declines (improvement of behavior): 34% for the Aberrant Behavior Checklist (P < 0.001, comparing treatments) and 17% for Social Responsiveness Scale scores (P = 0.017).|PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
sulforaphane	chemical_to_anatomy	, abnormal	1	0	25313065	PMID:25313065; Original text:On Clinical Global Impression Improvement Scale, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007).
memantine	chemical_to_anatomy	(clinical	1	0	27043118	PMID:27043118; Original text:Treatment with memantine was associated with significant reduction on informant-rated (SRS-A, -28 ± 25; P < 0.001) and clinician-rated (Clinical Global Impression-Improvement subscale ≤2, 83%) measures of autism severity.
cortisol	chemical_to_anatomy	, alpha	1	0	34237553	PMID:34237553; Original text:Data were analyzed with mixed models for outcome measures cortisol, alpha-amylase, heart rate variability and sympathetic activity.
cortisol	chemical_to_anatomy	, heart	1	0	34237553	PMID:34237553; Original text:Data were analyzed with mixed models for outcome measures cortisol, alpha-amylase, heart rate variability and sympathetic activity.
glutathione	chemical_to_anatomy	group	1	0	19852790	PMID:19852790; Original text:For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R2 of 0.28-0.75, p < 0.02 in all cases).
glutathione	chemical_to_anatomy	protein 1	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
glutathione	chemical_to_anatomy	b (	1	0	32745763	PMID:32745763; Original text:Modulation of glutathione is also associated with regulation of redox-sensitive transcription factors nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) and downstream signaling (proinflammatory cytokines and inducible enzymes), thus providing a significant impact on neuroinflammation.
glutathione	chemical_to_anatomy	mitochondrial	3	0	32745763|33493659|34034808	PMID:32745763; Original text:Mitochondrial dysfunction, as well as neuronal apoptosis, may also provide a significant link between glutathione metabolism and disorder.|PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.|PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
glutathione	chemical_to_anatomy	neuronal	2	0	32745763|33493659	PMID:32745763; Original text:Mitochondrial dysfunction, as well as neuronal apoptosis, may also provide a significant link between glutathione metabolism and disorder.|PMID:33493659; Original text:Neuronal apoptosis and mitochondrial dysfunction are recently outlined as significant factors linking glutathione impairments with the pathophysiology of disorder.
oxidized glutathione	chemical_to_anatomy	(p	1	0	32745763	PMID:32745763; Original text:Review analysis including research studies meeting the required criteria for analysis showed statistically significant differences between the plasma reduced glutathione and oxidized glutathione levels as well as reduced glutathione:oxidized glutathione ratio in autistic patients compared with healthy individuals (P = 0.0145, P = 0.0150 and P = 0.0202, respectively).
reduced glutathione	chemical_to_anatomy	(p	1	0	32745763	PMID:32745763; Original text:Review analysis including research studies meeting the required criteria for analysis showed statistically significant differences between the plasma reduced glutathione and oxidized glutathione levels as well as reduced glutathione:oxidized glutathione ratio in autistic patients compared with healthy individuals (P = 0.0145, P = 0.0150 and P = 0.0202, respectively).
aripiprazole	chemical_to_anatomy	(p	2	0	20973712|24502859	PMID:20973712; Original text:Statistically significantly greater improvement was seen with aripiprazole versus placebo (p < 0.05) for all arms in both trials on the the Aberrant Behavior Checklist-Irritability total subscale score and on the following individual the Aberrant Behavior Checklist-Irritability items: Mood changes quickly, cries/screams inappropriately, and stamps feet/bangs objects.|PMID:24502859; Original text:The difference in time to relapse between aripiprazole and placebo was not statistically significant (P = .097).
tantrum	chemical_to_anatomy	of the	1	0	20973712	PMID:20973712; Original text:Several additional items measuring tantrum-like behaviors improved in the flexibly dosed trial and at least one arm of the fixed-dose trial (p < 0.05).
tantrum	chemical_to_anatomy	(p	1	0	20973712	PMID:20973712; Original text:Several additional items measuring tantrum-like behaviors improved in the flexibly dosed trial and at least one arm of the fixed-dose trial (p < 0.05).
aripiprazole	chemical_to_anatomy	8	2	0	19797985|19797985	PMID:19797985; Original text:At week 8, all aripiprazole doses produced significantly greater improvement than placebo in mean Aberrant Behavior Checklist Irritability subscale scores (5 mg/day, -12.4; 10 mg/day, -13.2; 15 mg/day, -14.4; versus placebo, -8.4; all p < .05).|PMID:19797985; Original text:At week 8, mean weight change (last observation carried forward) was as follows: placebo +0.3 kg, aripiprazole 5 mg/day +1.3 kg, 10 mg/day +1.3 kg, and 15 mg/day +1.5 kg; all p < .05 versus placebo.
5-ht	chemical_to_anatomy	whole blood	1	0	24613076	PMID:24613076; Original text:Significantly higher 5-HT levels in autistic patients compared to controls were recorded both in whole blood (whole blood)
desipramine	chemical_to_anatomy	, and	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
desipramine	chemical_to_anatomy	(p	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
clomipramine	chemical_to_anatomy	, and	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
clomipramine	chemical_to_anatomy	(p	1	0	8498878	PMID:8498878; Original text:Clomipramine was superior to both placebo and desipramine on ratings of autistic symptoms (including stereotypies), anger, and compulsive, ritualized behaviors (P < .05), with no differences between desipramine and placebo.
risperidone	chemical_to_anatomy	i)	3	0	15930063|18080171|18080171	PMID:15930063; Original text:Compared to placebo, risperidone led to a significantly greater reduction in the overall score on the Ritvo-Freeman Real Life Rating Scale, as well as the scores on the subscales for sensory motor behaviors (subscale I), affectual reactions (subscale III), and sensory responses (subscale IV).|PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).
homocysteine	chemical_to_anatomy	levels of	2	0	24676906|24167375	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.|PMID:24167375; Original text:The urinary levels of homocysteine and essential amino acids in both the untreated and treated autistic children are significantly less than those in the controls.
homocysteine	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
glutathione	chemical_to_anatomy	levels of	2	0	24676906|22129897	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.|PMID:22129897; Original text:Recent evidence shows that subjects diagnosed with an autism spectrum disorder (disorder) have significantly lower levels of glutathione than typically developing children.
glutathione	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
methionine	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
s-adenosylhomocysteine	chemical_to_anatomy	levels of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
s-adenosylhomocysteine	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:The serum level of glutathione in autistic subjects was significantly below control levels, while levels of homocysteine and S-adenosylhomocysteine were elevated, indicative of oxidative stress and decreased methionine synthase activity.
mercury	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
folate	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
vitamin b₁₂.	chemical_to_anatomy	level of	1	0	24676906	PMID:24676906; Original text:We investigated the status of redox and methylation metabolites, as well as the level of protein homocysteinylation and hair mercury levels, in autistic and neurotypical control Omani children, who were previously shown to exhibit significant nutritional deficiencies in serum folate and vitamin B₁₂.
methyl b12	chemical_to_anatomy	of the	1	0	20804367	PMID:20804367; Original text:Comparison of the overall means between groups suggests that methyl B12 is ineffective in treating behavioral symptoms of autism.
p<0.05	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.05	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.05	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.05	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamine	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamine	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamine	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamine	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
cingulate	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
creatine	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.001	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.001	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.001	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
p<0.001	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
glutamate	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
phosphocreatine	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
phosphocreatine	chemical_to_anatomy	cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
phosphocreatine	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
phosphocreatine	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:In the disorder group in midline pregenual anterior cingulate cortex, we found mean 17.7% elevation of glutamate + glutamine (glutamate + glutamine) (p<0.05) and 21.2% (p<0.001) decrement in creatine + phosphocreatine (phosphocreatine).
n-acetyl-aspartate	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartate	chemical_to_anatomy	, and	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartate	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartate	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartyl-glutamate	chemical_to_anatomy	cingulate cortex	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartyl-glutamate	chemical_to_anatomy	, and	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartyl-glutamate	chemical_to_anatomy	anterior cingulate cortex	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
n-acetyl-aspartyl-glutamate	chemical_to_anatomy	anterior cingulate	1	0	22848344	PMID:22848344; Original text:Significant effects were restricted to right pregenual anterior cingulate cortex where glutamate + glutamine (9.5%, p<0.05), phosphocreatine (6.7%, p<0.05), and N-acetyl-aspartate + N-acetyl-aspartyl-glutamate (10.2%, p<0.01) in the disorder sample were elevated above control.
serotonin	chemical_to_anatomy	of the	4	0	18286633|18286633|3623815|22638012	PMID:18286633; Original text:The meta-analysis failed to find a significant overall association between either of the The serotonin transporter gene polymorphisms examined and autism.|PMID:18286633; Original text:However, there was significant heterogeneity by ethnicity; family based studies of US mixed population samples showed preferential transmission of the S allele of The serotonin transporter geneLPR (S allele:|PMID:3623815; Original text:The P300 component of the event-related potential (the event-related potential) was not affected by fenfluramine, although the drug significantly lowered blood concentrations of serotonin.|PMID:22638012; Original text:Modulation of the processing of facial expressions of emotion by serotonin significantly differs in people with ASD compared with control subjects.
tryptophan	chemical_to_anatomy	of the brain	1	0	28799778	PMID:28799778; Original text:The literature strongly suggests that Tryptophan has a significant role in the correct functionality of the brain-gut axis and immunology.
tryptophan	chemical_to_anatomy	the brain	1	0	28799778	PMID:28799778; Original text:The literature strongly suggests that Tryptophan has a significant role in the correct functionality of the brain-gut axis and immunology.
amino acids	chemical_to_anatomy	levels of	1	0	24167375	PMID:24167375; Original text:The urinary levels of homocysteine and essential amino acids in both the untreated and treated autistic children are significantly less than those in the controls.
cannabidiol	chemical_to_anatomy	brain	1	0	31237191	PMID:31237191; Original text:The 'fractional amplitude of low-frequency fluctuations' (fALFF) was measured across the whole brain, and, where its major non-intoxicating component cannabidiol significantly altered fALFF, we tested if functional connectivity (functional connectivity) of those regions was also affected by its major non-intoxicating component cannabidiol.
cannabidiol	chemical_to_anatomy	, and	1	0	31237191	PMID:31237191; Original text:The 'fractional amplitude of low-frequency fluctuations' (fALFF) was measured across the whole brain, and, where its major non-intoxicating component cannabidiol significantly altered fALFF, we tested if functional connectivity (functional connectivity) of those regions was also affected by its major non-intoxicating component cannabidiol.
cannabidiol	chemical_to_anatomy	cerebellar vermis	1	0	31237191	PMID:31237191; Original text:its major non-intoxicating component cannabidiol significantly increased fALFF in the cerebellar vermis and the right fusiform gyrus.
cannabidiol	chemical_to_anatomy	fusiform gyrus	1	0	31237191	PMID:31237191; Original text:its major non-intoxicating component cannabidiol significantly increased fALFF in the cerebellar vermis and the right fusiform gyrus.
polychlorinated biphenyls	chemical_to_anatomy	parts of	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
polychlorinated biphenyls	chemical_to_anatomy	parts of the	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
polychlorinated biphenyls	chemical_to_anatomy	of the	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
pcbs	chemical_to_anatomy	parts of	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
pcbs	chemical_to_anatomy	parts of the	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
pcbs	chemical_to_anatomy	of the	1	0	30976975	"PMID:30976975; Original text:Despite restrictions on the production of many of these compounds in most parts of the world through the Stockholm Convention on Persistent Organic Pollutants (Persistent Organic Pollutants), many ""legacy"" compounds, including polychlorinated biphenyls (PCBs), are routinely detected in human tissues where they continue to pose significant health risks to highly exposed and susceptible populations."
adenosine triphosphate	chemical_to_anatomy	mitochondrial	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
adenosine triphosphate	chemical_to_anatomy	the brain	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
adenosine triphosphate	chemical_to_anatomy	mast cell	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
adenosine triphosphate	chemical_to_anatomy	secretion of	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
adenosine triphosphate	chemical_to_anatomy	secretion	1	0	23688533	PMID:23688533; Original text:Neurotensin is significantly increased in serum of children with ASD and stimulates mast cell secretion of mitochondrial adenosine triphosphate and DNA, which is increased in these children; these mitochondrial components are misconstrued as innate pathogens, triggering an autoallergic response in the brain.
amino acids	chemical_to_anatomy	, and	1	0	21299356	PMID:21299356; Original text:Covering the literature from 1943 to the present in the PubMed and Ovid Medline databases, this review summarizes evidence of hormones, metabolites, amino acids, and other biomarkers present in significantly different quantities in autistic subjects compared to age- and sex-matched controls.
amino acids	chemical_to_anatomy	acids	1	0	21299356	PMID:21299356; Original text:Covering the literature from 1943 to the present in the PubMed and Ovid Medline databases, this review summarizes evidence of hormones, metabolites, amino acids, and other biomarkers present in significantly different quantities in autistic subjects compared to age- and sex-matched controls.
risperidone	chemical_to_anatomy	(p	8	0	16282839|15142390|18080171|18080171|18080171|16948927|14627879|16239862	PMID:16282839; Original text:The rates of correctly guessing individual treatment assignment (risperidone or placebo) were significantly greater than chance for both clinical evaluators and parents (P < 0.001).|PMID:15142390; Original text:In all children, serum prolactin levels increased significantly (p < 0.001) from 166 +/- 88 UI/mL at baseline to 504 +/- 207 UI/mL at week 12 of risperidone treatment.|PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).|PMID:18080171; Original text:Compared to haloperidol, risperidone led to a significantly greater reduction in the Aberrant Behavior Checklist (the Aberrant Behavior Checklist) and Turgay DSM-IV Pervasive Developmental Disorder (Turgay DSM-IV Pervasive Developmental Disorder) scale scores (P < 0.05 and P < 0.01).|PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).|PMID:14627879; Original text:Mean ratings at 8 weeks were 2.8 +/- 1.2 on risperidone and 4.5 +/- 1.3 on placebo (p <.001).|PMID:16239862; Original text:Risperidone was superior to placebo in preventing relapse: this occurred in 3 of 12 patients continuing on risperidone versus 8 of 12 who switched to placebo (p = .049).
oxygen	chemical_to_anatomy	of the	1	0	22987458	PMID:22987458; Original text:The mean total the Autism Treatment Evaluation Checklist score scores by both parents and clinicians were significantly improved after intervention in both arms of the study compared to the score before intervention (P < 0.001 in both groups by parents, P = 0.015 in hyperbaric oxygen therapy group and P = 0.004 in sham group by clinician).
oxygen	chemical_to_anatomy	(p	2	0	22987458|22987458	PMID:22987458; Original text:The mean total the Autism Treatment Evaluation Checklist score scores by both parents and clinicians were significantly improved after intervention in both arms of the study compared to the score before intervention (P < 0.001 in both groups by parents, P = 0.015 in hyperbaric oxygen therapy group and P = 0.004 in sham group by clinician).|PMID:22987458; Original text:On the other hand, for change scores (the Clinical Global ImpressionC) the clinicians indicated greater improvement following hyperbaric oxygen therapy (P = 0.03), but the parents found no such difference (P = 0.28).
oxygen	chemical_to_anatomy	groups	1	0	22987458	PMID:22987458; Original text:There were no statistically significant differences in average percentage changes of total the Autism Treatment Evaluation Checklist score score and all subscales scores when comparing the hyperbaric oxygen therapy and sham air groups, either by parents or clinicians.
oxytocin	chemical_to_anatomy	the brain	1	0	25416642	PMID:25416642; Original text:Here we extend our previous work by significantly increasing the number of participants to enable the use of more stringent statistical thresholds that permit more precise localization of oxytocin and vasopressin effects in the brain.
olanzapine	chemical_to_anatomy	(p	1	0	26792761	PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)
olanzapine	chemical_to_anatomy	, greater	1	0	26792761	PMID:26792761; Original text:In multivariable meta-regression analyses of 10 studies, greater cumulative T2DM risk was associated with longer follow-up (P < .001), olanzapine prescription (P < .001), and male sex (P = .002)
edc	chemical_to_anatomy	area of	1	0	34358505	PMID:34358505; Original text:This is a significant area of study as early brain development is heavily mediated by estrogen and could be particularly sensitive to EDC exposure.
estrogen	chemical_to_anatomy	area of	1	0	34358505	PMID:34358505; Original text:This is a significant area of study as early brain development is heavily mediated by estrogen and could be particularly sensitive to EDC exposure.
5-methyltetrahydrofolate	chemical_to_anatomy	cerebrospinal fluid	1	0	22230883	PMID:22230883; Original text:In 16 children, the concentration of blocking FRA significantly correlated with cerebrospinal fluid 5-methyltetrahydrofolate concentrations, which were below the normative mean in every case.
propentofylline	chemical_to_anatomy	(p	1	0	31725473	PMID:31725473; Original text:Compared with the placebo group, children receiving propentofylline showed greater improvements in the Childhood Autism Rating Scale score (P = 0.037) from baseline to the study endpoint.
propentofylline	chemical_to_anatomy	group	1	0	31725473	PMID:31725473; Original text:Compared with the placebo group, children receiving propentofylline showed greater improvements in the Childhood Autism Rating Scale score (P = 0.037) from baseline to the study endpoint.
fenfluramine	chemical_to_anatomy	group (	1	0	2977280	PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.
fenfluramine	chemical_to_anatomy	(p	1	0	2977280	PMID:2977280; Original text:Beta-endorphin was elevated significantly in the baseline autistic group (p less than .005) and was reduced toward control values during fenfluramine treatment.
sulforaphane	chemical_to_anatomy	positive	1	0	34034808	PMID:34034808; Original text:The effect sizes on the the Ohio Autism Clinical Impressions Scale were non-statistically significant but positive, suggesting a possible trend toward greater improvement in those on treatment with Sulforaphane (Cohen's d 0.21; 95% CI - 0.46, 0.88 and 0.10; 95% CI - 0.52, 0.72, respectively).
sulforaphane	chemical_to_anatomy	, mitochondrial	1	0	34034808	PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
sulforaphane	chemical_to_anatomy	mitochondrial	1	0	34034808	PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
glutathione	chemical_to_anatomy	, mitochondrial	1	0	34034808	PMID:34034808; Original text:There were significant changes with Sulforaphane compared to placebo in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins.
sulforaphane	chemical_to_anatomy	of the	1	0	34034808	PMID:34034808; Original text:Sulforaphane led to small yet non-statistically significant changes in the total and all subscale scores of the primary outcome measure, while for secondary outcome measures, caregivers' assessments of children taking Sulforaphane showed statistically significant improvements compared to those taking placebo on the the Aberrant Behavior Checklist but not the Scale-2.
comb	chemical_to_anatomy	group (	1	0	22265360	PMID:22265360; Original text:Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively).
comb	chemical_to_anatomy	, and	1	0	22265360	PMID:22265360; Original text:Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively).
comb	chemical_to_anatomy	(p	2	0	22265360|22265360	PMID:22265360; Original text:Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively).|PMID:22265360; Original text:Using logistic regression, children in the COMB group were twice as likely to make at least 6 months' gain (equal to the passage of time) in the Vineland Communication Age Equivalent score compared with MED (p = .02).
med	chemical_to_anatomy	(p	1	0	22265360	PMID:22265360; Original text:Using logistic regression, children in the COMB group were twice as likely to make at least 6 months' gain (equal to the passage of time) in the Vineland Communication Age Equivalent score compared with MED (p = .02).
vitamin d	chemical_to_anatomy	, a	1	0	28217829	PMID:28217829; Original text:In terms of prevention, a recent small study showed vitamin D supplementation during pregnancy (5000 IU/day) and during infancy and early childhood (1000 IU/day) significantly reduced the expected incidence of autism in mothers who already had one autistic child from 20% to 5%.
fluoxetine	chemical_to_anatomy	prefrontal cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	posterior cingulate cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	dorsolateral prefrontal cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	cingulate cortex	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	cortex (	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	posterior cingulate	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
fluoxetine	chemical_to_anatomy	dorsolateral prefrontal	1	0	25292351	PMID:25292351; Original text:Fluoxetine significantly normalized the the right dorsolateral prefrontal cortex underactivation in ASD relative to controls whereas it increased posterior cingulate cortex (PCC) deactivation in disorder relative to control boys.
vitamin	chemical_to_anatomy	levels of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
vitamin	chemical_to_anatomy	group of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b6	chemical_to_anatomy	levels of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b6	chemical_to_anatomy	group of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b(6	chemical_to_anatomy	levels of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
b(6	chemical_to_anatomy	group of	1	0	15673999	PMID:15673999; Original text:An evaluation of vitamin B(6) levels prior to the study found that the autistic children had substantially elevated levels of B6 compared to a control group of typical children (75% higher, p < 0.0000001).
vitamin c	chemical_to_anatomy	of the	1	0	15673999	PMID:15673999; Original text:Vitamin C levels were measured at the end of the study, and the placebo group had levels that were significantly below average for typical children, whereas the supplement group had near-average levels.
vitamin c	chemical_to_anatomy	end of	1	0	15673999	PMID:15673999; Original text:Vitamin C levels were measured at the end of the study, and the placebo group had levels that were significantly below average for typical children, whereas the supplement group had near-average levels.
vitamin c	chemical_to_anatomy	, and	1	0	15673999	PMID:15673999; Original text:Vitamin C levels were measured at the end of the study, and the placebo group had levels that were significantly below average for typical children, whereas the supplement group had near-average levels.
pyruvate	chemical_to_anatomy	mitochondrial	2	0	21263444|21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
ubiquinone	chemical_to_anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
lactate	chemical_to_anatomy	mitochondrial	2	0	21263444|21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.|PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
carnitine	chemical_to_anatomy	mitochondrial	1	0	21263444	PMID:21263444; Original text:Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls.
pyruvate	chemical_to_anatomy	, motor	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
pyruvate	chemical_to_anatomy	, gastrointestinal	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
pyruvate	chemical_to_anatomy	, and	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
pyruvate	chemical_to_anatomy	, female	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_anatomy	, motor	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_anatomy	, gastrointestinal	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_anatomy	, and	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
lactate	chemical_to_anatomy	, female	1	0	21263444	PMID:21263444; Original text:The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/concomitant mitochondrial disease compared with the general ASD population.
mercury	chemical_to_anatomy	, red	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	whole blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	red blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	cells (	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	blood cells	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
mercury	chemical_to_anatomy	, red blood	1	0	28965590	PMID:28965590; Original text:The mercury level in whole blood (Hedges=0.43, 95% its 95% corresponding confidence interval: 0.12, 0.74, P=0.007), red blood cells (Hedges=1.61, 95% its 95% corresponding confidence interval: 0.83, 2.38, P<0.001), and brain (0.61ng/g, 95% its 95% corresponding confidence interval, 0.02, 1.19, P=0.043) was significantly higher in spectrum disorders patients than healthy subjects, whereas mercury level in hair (-0.14mg/g, 95% its 95% corresponding confidence interval: -0.28, -0.01, P=0.039) was significantly lower in spectrum disorders patients than healthy subjects.
oxytocin	chemical_to_anatomy	anterior cingulate cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	chemical_to_anatomy	anterior cingulate	2	0	26336909|26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:26336909; Original text:Moreover, using the same social-judgement task as used in our previous single-dose oxytocin trial, we confirmed that the current continual administration also significantly mitigated behavioural and neural responses during the task, both of which were originally impaired in autistic individuals (judgement tendency: P = 0.019, d = 0.62; eye-gaze effect: P = 0.03, d = 0.56; anterior cingulate activity: P = 0.00069, d = 0.97; dorso-medial prefrontal activity: P = 0.0014, d = 0.92; all, PFDR < 0.05).
oxytocin	chemical_to_anatomy	cingulate cortex	1	0	26336909	PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.
oxytocin	chemical_to_anatomy	cortex and	2	0	26336909|32161366	"PMID:26336909; Original text:Critically, the improvement of this clinical score was accompanied by oxytocin-induced enhancement of task-independent resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex (rho = -0.60, P = 0.011), which was measured by functional magnetic resonance imaging.|PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
serotonin	chemical_to_anatomy	component of	1	0	3623815	PMID:3623815; Original text:The P300 component of the event-related potential (the event-related potential) was not affected by fenfluramine, although the drug significantly lowered blood concentrations of serotonin.
fenfluramine	chemical_to_anatomy	component of	1	0	3623815	PMID:3623815; Original text:The P300 component of the event-related potential (the event-related potential) was not affected by fenfluramine, although the drug significantly lowered blood concentrations of serotonin.
fenfluramine	chemical_to_anatomy	of the	1	0	3623815	PMID:3623815; Original text:The P300 component of the event-related potential (the event-related potential) was not affected by fenfluramine, although the drug significantly lowered blood concentrations of serotonin.
metformin	chemical_to_anatomy	, and	1	0	29620914	PMID:29620914; Original text:We studied the effects of metformin (Riomet®) concentrate on spatial and verbal memory in 51 youth with disorder, ages 6 through 17 years, who were taking atypical antipsychotic medications, had gained significant weight, and were enrolled in a trial of metformin for weight management.
riomet	chemical_to_anatomy	, and	1	0	29620914	PMID:29620914; Original text:We studied the effects of metformin (Riomet®) concentrate on spatial and verbal memory in 51 youth with disorder, ages 6 through 17 years, who were taking atypical antipsychotic medications, had gained significant weight, and were enrolled in a trial of metformin for weight management.
citalopram	chemical_to_anatomy	of the	1	0	24061784	PMID:24061784; Original text:Specifically, participants in the placebo group were significantly less likely than participants in the citalopram group to respond at week 12 if they entered the study more symptomatic on each of the 3 composite measures, and they were at least 2 times less likely to be responders.
citalopram	chemical_to_anatomy	, and	1	0	24061784	PMID:24061784; Original text:Specifically, participants in the placebo group were significantly less likely than participants in the citalopram group to respond at week 12 if they entered the study more symptomatic on each of the 3 composite measures, and they were at least 2 times less likely to be responders.
riluzole	chemical_to_anatomy	of peripheral	1	0	21059347	PMID:21059347; Original text:Overall, riluzole use was not associated with significant clinical improvement despite uniform correction of peripheral Extracellular signal-related kinase activation.
biotin	chemical_to_anatomy	levels of	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
biotin	chemical_to_anatomy	(p	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
vitamin k	chemical_to_anatomy	levels of	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
vitamin k	chemical_to_anatomy	(p	1	0	22151477	PMID:22151477; Original text:R2 = 0.61, p < 0.0005) with the initial levels of biotin and vitamin K being the most significant (p < 0.05); both biotin and vitamin K are made by beneficial intestinal flora.
atp	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadph	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nitrotyrosine	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
reduced glutathione	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
s	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
oxidized glutathione	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
nadh	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
gssg	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
sulfate	chemical_to_anatomy	, and	2	0	22151477|22129897	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).|PMID:22129897; Original text:Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
gsh	chemical_to_anatomy	, and	1	0	22151477	PMID:22151477; Original text:Statistically significant improvements in metabolic status were many including: total sulfate (+17%, p = 0.001), S-adenosylmethionine (SAM; +6%, p = 0.003), reduced glutathione (+17%, p = 0.0008), ratio of oxidized glutathione to reduced glutathione (GSSG:GSH; -27%, p = 0.002), nitrotyrosine (-29%, p = 0.004), ATP (+25%, p = 0.000001), NADH (+28%, p = 0.0002), and NADPH (+30%, p = 0.001).
lcpufa	chemical_to_anatomy	, and	1	0	28218722	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).
epa	chemical_to_anatomy	, and	2	0	28218722|29562612	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).|PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
dha	chemical_to_anatomy	, and	2	0	28218722|29562612	PMID:28218722; Original text:Compared with typically developed, Autism Spectrum Disorder populations had lower DHA (-2.14 [95% CI -3.22 to -1.07]; p < 0.0001; I² = 97%), EPA (-0.72 [95% CI -1.25 to -0.18]; p = 0.008; I² = 88%), and acid (-0.83 [95% CI, -1.48 to -0.17]; p = 0.01; I² = 96%) and higher total n-6 LCPUFA to n-3 LCPUFA ratio (0.42 [95% CI 0.06 to 0.78]; p = 0.02; I² = 74%).|PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
omega-3 fatty acids	chemical_to_anatomy	not rule	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
omega-3 fatty acids	chemical_to_anatomy	rule out	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
omega-3 fatty acids	chemical_to_anatomy	not rule out	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
omega-3 fatty acids	chemical_to_anatomy	acids	1	0	20683766	PMID:20683766; Original text:Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.
homocysteine	chemical_to_anatomy	of the	1	0	29437021	PMID:29437021; Original text:Some report demonstrated a significant association between the severity of the disorder and the abnormalities in Homocysteine levels.
fenfluramine	chemical_to_anatomy	, and	1	0	2682347	PMID:2682347; Original text:Electrophysiological data were affected according to the clinical and biochemical responsiveness to fenfluramine: the auditory evoked potential amplitude increased, and the single-trial potential variability decreased at each intensity level only in Six children whose dopaminergic metabolism was significantly modified by fenfluramine treatment.
tryptophan	chemical_to_anatomy	system	1	0	22638012	PMID:22638012; Original text:While some individuals with ASD have significant differences in the serotonin system, to our knowledge, no one has investigated its role during facial emotion processing in adults with ASD and control subjects using acute tryptophan depletion (acute tryptophan depletion) and functional magnetic resonance imaging.
serotonin	chemical_to_anatomy	system	1	0	22638012	PMID:22638012; Original text:While some individuals with ASD have significant differences in the serotonin system, to our knowledge, no one has investigated its role during facial emotion processing in adults with ASD and control subjects using acute tryptophan depletion (acute tryptophan depletion) and functional magnetic resonance imaging.
serotonin	chemical_to_anatomy	of facial	1	0	22638012	PMID:22638012; Original text:Modulation of the processing of facial expressions of emotion by serotonin significantly differs in people with ASD compared with control subjects.
serotonin	chemical_to_anatomy	of respiratory	1	0	25004304	PMID:25004304; Original text:Low-strength evidence suggested neonates of pregnant women with depression taking selective serotonin reuptake inhibitors had higher risk of respiratory distress than did neonates of untreated women (13.9% compared with 7.8%; P<.001) but no difference in risk of neonatal convulsions (0.14% compared with 0.11%; P=.64) or preterm birth (17% compared with 10%; P=.07).
oxytocin	chemical_to_anatomy	the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	chemical_to_anatomy	of the amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	chemical_to_anatomy	superior temporal	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	chemical_to_anatomy	temporal	2	0	32161366|8759044	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment.|PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_anatomy	orbitofrontal cortex	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	chemical_to_anatomy	amygdala	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
oxytocin	chemical_to_anatomy	temporal sulcus	1	0	32161366	"PMID:32161366; Original text:Using a double-blind, randomized, placebo-controlled, between-subject design (including 38 adult men with disorder), this treatment-mechanism study showed that 4 weeks of daily oxytocin administration (24 IU/day) significantly altered intrinsic (resting-state fMRI) functional connectivity of the amygdala to core regions of the ""social brain"" (particularly orbitofrontal cortex and superior temporal sulcus) up to 4 weeks and 1 year post treatment."
fluvoxamine	chemical_to_anatomy	group (	1	0	8911223	PMID:8911223; Original text:Eight (53%) of 15 patients in the fluvoxamine-treated group were categorized as responders compared with none of 15 in the placebo group (P = .001).
fluvoxamine	chemical_to_anatomy	(p	2	0	8911223|8911223	PMID:8911223; Original text:Eight (53%) of 15 patients in the fluvoxamine-treated group were categorized as responders compared with none of 15 in the placebo group (P = .001).|PMID:8911223; Original text:Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior (P < .001), maladaptive behavior (P < .001), and aggression (P < .03), and in improving some aspects of social relatedness (P < .04), especially language usage (P < .008).
vitamin d	chemical_to_anatomy	of the	2	0	32294031|33383952	PMID:32294031; Original text:Significant vitamin D deficiency is described within children affected by Autism Spectrum Disorder and in pregnant mothers whose offspring will later develop Autism Spectrum Disorder, suggesting a possible role of the hormone as a contributing risk factor in the etiopathogenesis of Autism Spectrum Disorder.|PMID:33383952; Original text:Meta-analysis of 24 case-control studies demonstrated that children and adolescents with disorder had significantly lower vitamin D concentration than that of the control group (mean difference (MD): -7.46 ng/mL, 95% confidence interval (95% confidence interval): -10.26; -4.66 ng/mL, p < 0.0001, I = 98%).
folate	chemical_to_anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_anatomy	, a	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_anatomy	, and	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
folate	chemical_to_anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_anatomy	, can	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_anatomy	, a	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_anatomy	, and	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_anatomy	,l	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
d	chemical_to_anatomy	pathway	1	0	32892962	PMID:32892962; Original text:Most significantly, case-series, open-label, and single and double-blind placebo-controlled studies suggest that d,l-leucovorin, a reduced folate that can bypass the blockage at the folate receptor alpha by using the reduced folate carrier, an alternate pathway, can substantially improve particular symptoms in children with disorder, especially those positive for folate receptor alpha autoantibodies.
cobalt	chemical_to_anatomy	, and	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
cobalt	chemical_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
magnesium	chemical_to_anatomy	, and	2	0	28665792|3886023	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).|PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
magnesium	chemical_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	chemical_to_anatomy	, and	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iron	chemical_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	chemical_to_anatomy	, and	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
chromium	chemical_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iodine	chemical_to_anatomy	, and	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
iodine	chemical_to_anatomy	hair of	1	0	28665792	PMID:28665792; Original text:Meta-analyses showed that the hair concentrations of chromium (p=0.024), cobalt (p=0.012), iodine (p=0.000), iron (p=0.017), and magnesium (p=0.007) in disorder patients were significantly lower than those of control subjects, while there were higher magnesium levels in the hair of disorder patients compared to that of controls (p=0.010).
copper	chemical_to_anatomy	levels of	2	0	28665792|34049201	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).|PMID:34049201; Original text:There were significant differences in the levels of copper (copper) in the hair and serum between autistic children and the control group.
zinc	chemical_to_anatomy	levels of	1	0	28665792	PMID:28665792; Original text:Patients with disorder had higher blood levels of copper (p=0.000) and lower levels of zinc compared to controls (p=0.021).
carnitine	chemical_to_anatomy	, and	2	0	21629200|29562612	PMID:21629200; Original text:Significant correlations between changes in serum free-carnitine levels and positive clinical changes were observed for hand muscle strength (R2=0.23, P=0.046), cognitive scores (R2=0.27, P=0.019), and Childhood Autism Rating Scale scores (R2=0.20, P=0.047).|PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
melatonin	chemical_to_anatomy	, and	2	0	19968048|12804129	PMID:19968048; Original text:The conclusions from a nonparametric repeated-measures technique indicate that mean night sleep duration was longer on melatonin than placebo by 21 minutes (p = .02), mean sleep-onset latency was shorter by 28 minutes (p = .0001), and mean sleep-onset time was earlier by 42 minutes (p = .02).|PMID:12804129; Original text:Despite the short duration of the treatment, behavioral measures also displayed a significant improvement, and most of the effect disappeared after the discontinuation of the melatonin (p = 0.001).
melatonin	chemical_to_anatomy	(p	2	0	19968048|12804129	PMID:19968048; Original text:The conclusions from a nonparametric repeated-measures technique indicate that mean night sleep duration was longer on melatonin than placebo by 21 minutes (p = .02), mean sleep-onset latency was shorter by 28 minutes (p = .0001), and mean sleep-onset time was earlier by 42 minutes (p = .02).|PMID:12804129; Original text:Despite the short duration of the treatment, behavioral measures also displayed a significant improvement, and most of the effect disappeared after the discontinuation of the melatonin (p = 0.001).
pten	chemical_to_anatomy	neural stem	1	0	24136242	PMID:24136242; Original text:Particularly, accumulated data suggest that the effect of PTEN on neural stem-cell development contributes significantly to the pathophysiology of autism spectrum disorders.
synthesize	chemical_to_anatomy	of the	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
cholesterol	chemical_to_anatomy	of the	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
steroid	chemical_to_anatomy	of the	1	0	10959439	PMID:10959439; Original text:Most significant clinically has been the realization that many of the postnatal clinical problems of patients with Smith-Lemli-Opitz syndrome are direct consequences of the inability to synthesize the large amounts of cholesterol needed for growth and for the synthesis of compounds derived from cholesterol, such as steroid hormones.
dopamine	chemical_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical_to_anatomy	, and	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
dopamine	chemical_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical_to_anatomy	, and	2	0	32305492|3886023	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.|PMID:3886023; Original text:The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary homovanillic acid excretion decreased, and EP amplitude and morphology seemed to be normalized.
homovanillic acid	chemical_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
homovanillic acid	chemical_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
serotonin	chemical_to_anatomy	, and	3	0	32305492|15730889|6502317	"PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.|PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors.|PMID:6502317; Original text:Significant correlations emerged among the amount of clinical response, initially high verbal IQs, and low blood serotonin concentrations."
serotonin	chemical_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
serotonin	chemical_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical_to_anatomy	, and	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
propionic acid	chemical_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical_to_anatomy	, and	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
butyric acid	chemical_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical_to_anatomy	levels of	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical_to_anatomy	, and	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical_to_anatomy	acid	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
acetic acid	chemical_to_anatomy	group	1	0	32305492	PMID:32305492; Original text:Compared to children in the control group, significantly lower levels of acetic acid, propionic acid and butyric acid were found, and a hyperserotonergic state (increased serotonin) and dopamine metabolism disorder (decreased homovanillic acid) were observed in children with ASD.
carbohydrate-	chemical_to_anatomy	of the	1	0	12858328	PMID:12858328; Original text:The carbohydrate-rich meal test (The carbohydrate-rich meal test) is a dietary manipulation that could significantly influence platelet-poor plasma (platelet-poor plasma) 5-HT levels and reflect the responsiveness of the serotonergic system in 'free' plasma.
carbohydrate-	chemical_to_anatomy	platelet	1	0	12858328	PMID:12858328; Original text:The carbohydrate-rich meal test (The carbohydrate-rich meal test) is a dietary manipulation that could significantly influence platelet-poor plasma (platelet-poor plasma) 5-HT levels and reflect the responsiveness of the serotonergic system in 'free' plasma.
5-ht	chemical_to_anatomy	of the	1	0	12858328	PMID:12858328; Original text:The carbohydrate-rich meal test (The carbohydrate-rich meal test) is a dietary manipulation that could significantly influence platelet-poor plasma (platelet-poor plasma) 5-HT levels and reflect the responsiveness of the serotonergic system in 'free' plasma.
5-ht	chemical_to_anatomy	platelet	2	0	12858328|12858328	PMID:12858328; Original text:The carbohydrate-rich meal test (The carbohydrate-rich meal test) is a dietary manipulation that could significantly influence platelet-poor plasma (platelet-poor plasma) 5-HT levels and reflect the responsiveness of the serotonergic system in 'free' plasma.|PMID:12858328; Original text:A significant elevation in platelet-poor plasma 5-HT levels in adult autistic patients was reached 60 min after meal administration (p < 0.03 vs control and p = 0.05 vs baseline) and a significant decrease was noted after 120 min (p < 0.01 vs baseline).
5-ht	chemical_to_anatomy	(p	1	0	12858328	PMID:12858328; Original text:A significant elevation in platelet-poor plasma 5-HT levels in adult autistic patients was reached 60 min after meal administration (p < 0.03 vs control and p = 0.05 vs baseline) and a significant decrease was noted after 120 min (p < 0.01 vs baseline).
risperidone	chemical_to_anatomy	, sensory motor	1	0	18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).
risperidone	chemical_to_anatomy	, sensory	1	0	18080171	PMID:18080171; Original text:The reduction from baseline in Ritvo-Freeman Real Life Rating Scale (Ritvo-Freeman Real Life Rating Scale), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group (P < 0.05).
haloperidol	chemical_to_anatomy	(p	1	0	18080171	PMID:18080171; Original text:Compared to haloperidol, risperidone led to a significantly greater reduction in the Aberrant Behavior Checklist (the Aberrant Behavior Checklist) and Turgay DSM-IV Pervasive Developmental Disorder (Turgay DSM-IV Pervasive Developmental Disorder) scale scores (P < 0.05 and P < 0.01).
risperidone	chemical_to_anatomy	end of	2	0	18080171|31063671	PMID:18080171; Original text:Sensory motor behaviors (subscale I) and language at the end of the 12th week, Ritvo-Freeman Real Life Rating Scale sensory motor and language subscale scores decreased in the risperidone group further than the other group (P < 0.05).|PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
serotonin	chemical_to_anatomy	cortex	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	chemical_to_anatomy	receptors	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
serotonin	chemical_to_anatomy	terminals	1	0	15730889	"PMID:15730889; Original text:In published reports, these animals have been found to have a significant loss of serotonin terminals, decreased metabolic activity in cortex, changes in columnar development in cortex, changes in serotonin receptors, and ""autistic-like"" behaviors."
rs6280	chemical_to_anatomy	, 3	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
rs6280	chemical_to_anatomy	3 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
rs6280	chemical_to_anatomy	, 2	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
rs6280	chemical_to_anatomy	2 of	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
risperidone	chemical_to_anatomy	, 3	1	0	33222504	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.
risperidone	chemical_to_anatomy	3 of	2	0	33222504|16239862	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.|PMID:16239862; Original text:Risperidone was superior to placebo in preventing relapse: this occurred in 3 of 12 patients continuing on risperidone versus 8 of 12 who switched to placebo (p = .049).
risperidone	chemical_to_anatomy	, 2	2	0	33222504|24828014	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.|PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
risperidone	chemical_to_anatomy	2 of	3	0	33222504|24828014|16948927	PMID:33222504; Original text:Most interesting results for response were reported for 2 sets of candidate gene studies, namely: (1) The DRD3 Ser9Gly (rs6280) polymorphism was examined in patients treated with risperidone in 3 studies, 2 of which reported an association with risperidone treatment response and (2) the SLC6A4 5-HTTLPR polymorphism and treatment response to antidepressants which was investigated in 4 studies, 3 of which reported significant associations.|PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).|PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
25(oh)d	chemical_to_anatomy	l (	1	0	28626020	PMID:28626020; Original text:Following vitamin D3 supplementation, there was a significant increase in 25(OH)D to 83.8 nmol/L (p=0.0016) but no effect on the primary endpoint.
vitamin d3	chemical_to_anatomy	l (	1	0	28626020	PMID:28626020; Original text:Following vitamin D3 supplementation, there was a significant increase in 25(OH)D to 83.8 nmol/L (p=0.0016) but no effect on the primary endpoint.
fatty acids	chemical_to_anatomy	levels of	1	0	33669008	PMID:33669008; Original text:Non-short-chain fatty acids yielded less significantly distinct changes in faecal levels of patients and healthy controls, with the majority of findings were derived from urinary and blood samples.
sulforaphane	chemical_to_anatomy	(primary	1	0	32347624	PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
sulforaphane	chemical_to_anatomy	group	1	0	32347624	PMID:32347624; Original text:Compared to the placebo group, disorder patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time × Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008).
n-acetylcysteine	chemical_to_anatomy	group (	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
n-acetylcysteine	chemical_to_anatomy	(p	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
n-acetylcysteine	chemical_to_anatomy	12	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
glutathione	chemical_to_anatomy	group (	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
glutathione	chemical_to_anatomy	(p	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
glutathione	chemical_to_anatomy	12	1	0	27103982	PMID:27103982; Original text:At week 12, there was no statistically significant difference between the oral N-acetylcysteine and placebo groups on the the Clinical Global Impressions Improvement (p > 0.69) but the glutathione (the glutathione) level in blood was significantly higher in the oral N-acetylcysteine group (p < 0.05).
fluoxetine	chemical_to_anatomy	cingulate gyrus	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
fluoxetine	chemical_to_anatomy	anterior cingulate	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
fluoxetine	chemical_to_anatomy	anterior cingulate gyrus	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
fluoxetine	chemical_to_anatomy	orbitofrontal cortex	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
fluoxetine	chemical_to_anatomy	frontal lobe	1	0	11466160	PMID:11466160; Original text:Relative metabolic rates were significantly higher in the right frontal lobe following fluoxetine, especially in the anterior cingulate gyrus and the orbitofrontal cortex.
buspirone	chemical_to_anatomy	(p	2	0	26746121|26746121	PMID:26746121; Original text:There was no difference in the the Autism Diagnostic Observation Schedule Composite Total Score between baseline and 24 weeks among the 3 treatment groups (P = .400); however, the the Autism Diagnostic Observation Schedule Restricted and Repetitive Behavior score showed a time-by-treatment effect (P = .006); the 2.5-mg buspirone group showed significant improvement (P = .003), whereas placebo and 5.0-mg buspirone groups showed no change.|PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
buspirone	chemical_to_anatomy	levels of	1	0	26746121	PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
buspirone	chemical_to_anatomy	of blood	1	0	26746121	PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
tryptophan	chemical_to_anatomy	levels of	1	0	26746121	PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
tryptophan	chemical_to_anatomy	of blood	1	0	26746121	PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
serotonin	chemical_to_anatomy	of blood	1	0	26746121	PMID:26746121; Original text:Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P = .018) or if they showed normal levels of blood serotonin (P = .044).
glutamate	chemical_to_anatomy	ci)	1	0	27390857	PMID:27390857; Original text:The meta-analysis provided evidence for higher blood glutamate levels in disorder [the pooled standardized mean difference = 0.99, 95% confidence interval (95% CI) = 0.58-1.40; P < 0.001] with high heterogeneity (I2 = 86%, P < 0.001) across studies.
vitamin b6	chemical_to_anatomy	level of	1	0	16494569	PMID:16494569; Original text:Children with autism had a 75% higher level of total vitamin B6 than the controls (medians of 56 versus 32 ng/mL, respectively, p = 0.00002).
androgens	chemical_to_anatomy	of the	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
androgens	chemical_to_anatomy	, and	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
and	chemical_to_anatomy	of the	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
and	chemical_to_anatomy	, and	1	0	22508080	PMID:22508080; Original text:Data from multiple animals and human clinical trials suggest that antiandrogen medications have the ability to significantly reduce traits in patients diagnosed with an Asperger's syndromeD. In light of the robust association between hyperandrogenism and Asperger's syndromeD, it is recommended subjects diagnosed with an Asperger's syndromeD should undergo routine screening for elevated androgens, and appropriate treatment should be initiated for those with elevated androgens.
glucose	chemical_to_anatomy	, and	2	0	21813076|27126856	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.|PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
cholesterol	chemical_to_anatomy	, and	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
triglycerides	chemical_to_anatomy	, and	1	0	21813076	PMID:21813076; Original text:The percentages of subjects with clinically significant fasting metabolic abnormalities at > 9 months were 2% for glucose, 5% for total cholesterol, 7% for low-density lipoprotein cholesterol, 30% for high-density lipoprotein cholesterol, and 5% for triglycerides.
naa	chemical_to_anatomy	of lower	1	0	22832731	PMID:22832731; Original text:Meta-regression analysis further revealed that the effect size of lower frontal NAA levels linearly declined with older mean age in ASD (n=844, P<0.05 Bonferroni-corrected).
oxygen	chemical_to_anatomy	contact	1	0	19284641	PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.
oxygen	chemical_to_anatomy	, eye	1	0	19284641	PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.
oxygen	chemical_to_anatomy	, and	1	0	19284641	PMID:19284641; Original text:Children with autism who received hyperbaric tre1.3 atmosphereent at 1.3 1.3 atmosphere and 24% oxygen for 40 hourly sessions had significant improvements in overall functioning, receptive language, social interaction, eye contact, and sensory/cognitive awareness compared to children who received slightly pressurized room air.
dcs	chemical_to_anatomy	, and	1	0	28138381	PMID:28138381; Original text:Study participants included 60 outpatient youth with disorder, ages 5-11 years, all with IQ above 70, and significantly impaired social functioning who completed a 10-week active treatment phase during which they received weekly single doses of 50 mg of DCS or placebo administered 30 min prior to group social skills training.
risperidone	chemical_to_anatomy	monocyte	1	0	24828014	PMID:24828014; Original text:After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines showed statistically significant decreases in median levels: Eotaxin (p=0.0003) and monocyte chemoattractant protein-1 (monocyte chemoattractant protein-1) (p=0.0024).
epa	chemical_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
epa	chemical_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical_to_anatomy	, and	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
coenzyme q10	chemical_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
vitamins a	chemical_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
vitamins a	chemical_to_anatomy	, and	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
vitamins a	chemical_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	chemical_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	chemical_to_anatomy	, and	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
folic acid	chemical_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
dha	chemical_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
dha	chemical_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical_to_anatomy	, b2	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
carnitine	chemical_to_anatomy	acid	1	0	29562612	PMID:29562612; Original text:The treatment group had significantly greater increases in EPA, DHA, carnitine, and vitamins A, B2, B5, B6, B12, folic acid, and Coenzyme Q10.
arsenic	chemical_to_anatomy	blood	1	0	31549506	PMID:31549506; Original text:In the following meta-analysis, we found statistically significant higher Inorganic arsenic concentrations, in hair and in blood, for children diagnosed with disorder compared with controls across studies.
pb	chemical_to_anatomy	, and	1	0	31549506	PMID:31549506; Original text:However, the findings on Pb exposure were inconsistent, with a significant association for hair Pb, no association for urinary Pb, and an inverse association for blood Pb.
ps128	chemical_to_anatomy	of the	1	0	30979038	PMID:30979038; Original text:The results showed that PS128 ameliorated opposition/defiance behaviors, and that the total score of The Swanson, Nolan, and Pelham-IV-Taiwan version for younger children (aged 712) improved significantly compared with the placebo group.
ps128	chemical_to_anatomy	, and	1	0	30979038	PMID:30979038; Original text:The results showed that PS128 ameliorated opposition/defiance behaviors, and that the total score of The Swanson, Nolan, and Pelham-IV-Taiwan version for younger children (aged 712) improved significantly compared with the placebo group.
25(oh)	chemical_to_anatomy	levels of	1	0	26514973	PMID:26514973; Original text:Levels of serum 25(OH)
gaba+	chemical_to_anatomy	prefrontal cortex	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
gaba+	chemical_to_anatomy	regions	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
gaba	chemical_to_anatomy	prefrontal cortex	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
gaba	chemical_to_anatomy	regions	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
cannabidiol	chemical_to_anatomy	prefrontal cortex	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
cannabidiol	chemical_to_anatomy	regions	1	0	30758329	PMID:30758329; Original text:Across regions, its major non-intoxicating component cannabidiol increased GABA+ in controls, but decreased GABA+ in ASD; the group difference in change in GABA + in the the dorsomedial prefrontal cortex was significant.
risperidone	chemical_to_anatomy	and 2	1	0	16948927	PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
risperidone	chemical_to_anatomy	group	1	0	16948927	PMID:16948927; Original text:In the risperidone group, 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children's Global Assessment Scale score in the placebo group (P < .001 and P = .035, respectively).
simvastatin	chemical_to_anatomy	(i)	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
simvastatin	chemical_to_anatomy	white matter	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
simvastatin	chemical_to_anatomy	i)	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
simvastatin	chemical_to_anatomy	(i	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
gaba	chemical_to_anatomy	(i)	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
gaba	chemical_to_anatomy	white matter	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
gaba	chemical_to_anatomy	i)	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
gaba	chemical_to_anatomy	(i	1	0	29484149	PMID:29484149; Original text:Simvastatin treatment was associated with (i) increased frontal white matter MRS GABA (t(12)
riluzole	chemical_to_anatomy	, and	1	0	23821414	PMID:23821414; Original text:Forty-nine patients were enrolled in the study, and forty children completed the trial (dropouts: placebo = 4, riluzole = 5).
riluzole	chemical_to_anatomy	4	1	0	23821414	PMID:23821414; Original text:Forty-nine patients were enrolled in the study, and forty children completed the trial (dropouts: placebo = 4, riluzole = 5).
riluzole	chemical_to_anatomy	group (	1	0	23821414	PMID:23821414; Original text:A significantly greater improvement in the study primary outcome (the ABC-C irritability subscale score) was achieved by the riluzole-treated children compared with the placebo group (P = 0.03).
riluzole	chemical_to_anatomy	(p	1	0	23821414	PMID:23821414; Original text:A significantly greater improvement in the study primary outcome (the ABC-C irritability subscale score) was achieved by the riluzole-treated children compared with the placebo group (P = 0.03).
riluzole	chemical_to_anatomy	of the	1	0	23821414	PMID:23821414; Original text:Children in the riluzole group experienced significantly more increases in their appetite and bodyweight than children in the placebo group by the end of the study.
riluzole	chemical_to_anatomy	end of	1	0	23821414	PMID:23821414; Original text:Children in the riluzole group experienced significantly more increases in their appetite and bodyweight than children in the placebo group by the end of the study.
3,4	chemical_to_anatomy	group (	1	0	30196397	PMID:30196397; Original text:Improvement in LSAS scores from baseline to the primary endpoint was significantly greater for 3,4-methylenedioxymethamphetamine group compared to the placebo group (P = 0.037), and placebo-subtracted Cohen's d effect size was very large (d = 1.4, CI - 0.074, 2.874).
3,4	chemical_to_anatomy	, and	1	0	30196397	PMID:30196397; Original text:Improvement in LSAS scores from baseline to the primary endpoint was significantly greater for 3,4-methylenedioxymethamphetamine group compared to the placebo group (P = 0.037), and placebo-subtracted Cohen's d effect size was very large (d = 1.4, CI - 0.074, 2.874).
3,4	chemical_to_anatomy	(p	1	0	30196397	PMID:30196397; Original text:Improvement in LSAS scores from baseline to the primary endpoint was significantly greater for 3,4-methylenedioxymethamphetamine group compared to the placebo group (P = 0.037), and placebo-subtracted Cohen's d effect size was very large (d = 1.4, CI - 0.074, 2.874).
pregnenolone	chemical_to_anatomy	of the	1	0	32947424	PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
pregnenolone	chemical_to_anatomy	, and	1	0	32947424	PMID:32947424; Original text:Repeated measures analysis was suggestive of greater exhibited improvement for the pregnenolone group on irritability, stereotypy, and hyperactivity subscales of the Aberrant Behavior Checklist-Community Edition over the trial period (F = 3.84, df = 1.96, P = 0.025; F = 4.29, df = 1.39, P = 0.029; F = 6.55, df = 1.67, P = 0.004, respectively).
vitamin d	chemical_to_anatomy	levels of	1	0	32966919	PMID:32966919; Original text:Serum levels of 25(25-hydroxyvitamin)D increased significantly in the vitamin D group (P = 0.001).
vitamin d	chemical_to_anatomy	group (	3	0	32966919|33383952|33383952	PMID:32966919; Original text:Serum levels of 25(25-hydroxyvitamin)D increased significantly in the vitamin D group (P = 0.001).|PMID:33383952; Original text:Meta-analysis of 24 case-control studies demonstrated that children and adolescents with disorder had significantly lower vitamin D concentration than that of the control group (mean difference (MD): -7.46 ng/mL, 95% confidence interval (95% confidence interval): -10.26; -4.66 ng/mL, p < 0.0001, I = 98%).|PMID:33383952; Original text:Furthermore, meta-analysis of maternal and neonatal vitamin D showed a trend of decreased early-life vitamin D concentration in the disorder group (MD: -3.15, 95% 95% confidence interval: -6.57; 0.26, p = 0.07, I = 99%).
vitamin d	chemical_to_anatomy	(p	1	0	32966919	PMID:32966919; Original text:Serum levels of 25(25-hydroxyvitamin)D increased significantly in the vitamin D group (P = 0.001).
homocysteine	chemical_to_anatomy	peripheral blood	1	0	32763544	PMID:32763544; Original text:The pooled results showed that the peripheral blood homocysteine levels were significantly elevated in children with disorder when compared to healthy controls (Hedges's g = 0.56, 95% CI = 0.36 to 0.76, P < 0.001).
oxytocin	chemical_to_anatomy	of primary	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_anatomy	neuronal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_anatomy	of temporal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
oxytocin	chemical_to_anatomy	parietal	1	0	8759044	"PMID:8759044; Original text:Behavioral impairments in autism are theorized to result from abnormal neuronal organization in brain development generating 4 systemically related neurofunctional impairments: (a) canalesthesia, wherein abnormal hippocampal system function ""canalizes"" sensory records, disrupting integration of information; (b) impaired assignment of the affective significance of stimuli, wherein abnormal amygdaloid system function disrupts affect association; (c) asociality, wherein impaired oxytocin system function flattens social bonding and affiliativeness; and (d) extended selective attention, wherein abnormal organization of temporal and parietal polysensory regions yields aberrant overprocessing of primary representations."
paracetamol	chemical_to_anatomy	ductus arteriosus	2	0	31985831|29624206	PMID:31985831; Original text:Two studies compared prophylactic administration of paracetamol for a the patent ductus arteriosus with placebo or no intervention in 80 infants.|PMID:29624206; Original text:Two studies compared prophylactic administration of paracetamol for a the patent ductus arteriosus with placebo or no intervention in 80 infants.
taurine	chemical_to_anatomy	, and	1	0	22129897	PMID:22129897; Original text:Both the oral and transdermal treatment groups showed significant increases in plasma sulfate, cysteine, and taurine following supplementation.
pregnenolone	chemical_to_anatomy	(p	1	0	24849255	PMID:24849255; Original text:Pregnenolone yielded a statistically significant improvement in the primary measure, Aberrant Behavior Checklist (ABC)-Irritability [from 17.4 ± 7.4 at baseline to 11.2 ± 7.0 at 12 weeks (p = 0.028)].
p-cresol sulfate	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Although not statistically significant, p-cresol sulfate was relatively higher in the disorder group at baseline, and after Microbiota transfer therapy, the levels decreased and were similar to levels in typically developing (TD) controls.
leucylglycine	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
heptanoate	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
methylsuccinate	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
valylglycine	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
imp	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
caprylate	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
galactonate	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
nicotinamide riboside	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
iminodiacetate	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
sarcosine	chemical_to_anatomy	, and	1	0	33087514	PMID:33087514; Original text:Eight metabolites (nicotinamide riboside, IMP, iminodiacetate, methylsuccinate, galactonate, valylglycine, sarcosine, and leucylglycine) were significantly lower in the disorder group at baseline, while caprylate and heptanoate were significantly higher in the disorder group.
dmsa	chemical_to_anatomy	, and	1	0	19852789	PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
dmsa	chemical_to_anatomy	platelet	1	0	19852789	PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
glutathione	chemical_to_anatomy	platelet	1	0	19852789	PMID:19852789; Original text:The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
folinic acid	chemical_to_anatomy	group (	1	0	32387472	PMID:32387472; Original text:The global ADOS score and social interaction and communication sub scores were significantly improved at week 12 compared to baseline in the folinic acid group (P = 0.003, P = 0.004 and P = 0.022, respectively), but not in the placebo group (P = 0.574, P = 0.780, P = 0.269, respectively).
folinic acid	chemical_to_anatomy	(p	1	0	32387472	PMID:32387472; Original text:The global ADOS score and social interaction and communication sub scores were significantly improved at week 12 compared to baseline in the folinic acid group (P = 0.003, P = 0.004 and P = 0.022, respectively), but not in the placebo group (P = 0.574, P = 0.780, P = 0.269, respectively).
glucose	chemical_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
glucose	chemical_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine	chemical_to_anatomy	, and	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine	chemical_to_anatomy	(p	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
alanine	chemical_to_anatomy	16	1	0	27126856	PMID:27126856; Original text:From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001).
venlafaxine	chemical_to_anatomy	(p	1	0	26361994	PMID:26361994; Original text:Univariate analyses showed that the symptom of irritability improved in the entire sample (p = 0.023 after 2 weeks, p = 0.061 at study endpoint), although no difference was observed between the venlafaxine and placebo groups.
ammonia	chemical_to_anatomy	2	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
ammonia	chemical_to_anatomy	28	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
ammonia	chemical_to_anatomy	set of	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
ammonia	chemical_to_anatomy	, and	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
ammonia	chemical_to_anatomy	test	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical_to_anatomy	2	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical_to_anatomy	28	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical_to_anatomy	set of	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical_to_anatomy	, and	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical_to_anatomy	test	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
zuclopenthixol	chemical_to_anatomy	2	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
zuclopenthixol	chemical_to_anatomy	28	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
zuclopenthixol	chemical_to_anatomy	set of	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
zuclopenthixol	chemical_to_anatomy	, and	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
zuclopenthixol	chemical_to_anatomy	test	1	0	26361994	PMID:26361994; Original text:For an additional set of variables (the Aberrant Behavior Checklist factor 2, Behavior Problems Inventory frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser–Meyer–Olkin Measure of Sampling Adequacy was below the accepted threshold.
clonazepam	chemical_to_anatomy	group	1	0	26361994	PMID:26361994; Original text:Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant.
venlafaxine	chemical_to_anatomy	group	1	0	26361994	PMID:26361994; Original text:Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant.
zuclopenthixol	chemical_to_anatomy	group	1	0	26361994	PMID:26361994; Original text:Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant.
aripiprazole	chemical_to_anatomy	end of	1	0	31063671	PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
a	chemical_to_anatomy	end of	1	0	31063671	PMID:31063671; Original text:Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial.
risperidone	chemical_to_anatomy	(primary	1	0	15492353	PMID:15492353; Original text:Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the the Aberrant Behavior Checklist (primary endpoint) compared with those who were taking placebo.
n	chemical_to_anatomy	medial prefrontal	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamine	chemical_to_anatomy	medial prefrontal	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
glutamate	chemical_to_anatomy	medial prefrontal	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
naa	chemical_to_anatomy	medial prefrontal	1	0	30262887	PMID:30262887; Original text:As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
